CONSOLIDATED BALANCE SHEETS (USD $) In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash and cash equivalents	$ 5,571	$ 3,586
Marketable securities, current	1,864	939
Receivables	3,390	3,360
Inventories	1,560	1,498
Deferred income taxes, current	1,644	1,701
Prepaid expenses and other	470	412
Assets held-for-sale	109	7,420
Total Current Assets	14,608	18,916
Property, plant and equipment	4,417	4,579
Goodwill	7,027	7,096
Other intangible assets	1,753	2,318
Deferred income taxes	915	508
Marketable securities, noncurrent	4,408	3,747
Other assets	621	1,428
Total Assets	33,749	38,592
Current Liabilities:
Short-term borrowings	590	359
Accounts payable	2,487	2,559
Accrued expenses	2,459	2,152
Deferred income, current	1,167	756
Accrued rebates and returns	851	889
Income taxes payable, current	262	160
Dividends payable	645	634
Liabilities related to assets held-for-sale		4,931
Total Current Liabilities	8,461	12,440
Pension, postretirement, and postemployment liabilities	1,115	718
Deferred income, noncurrent	770	769
Income taxes payable, noncurrent	560	823
Other liabilities	618	625
Long-term debt	7,242	7,981
Total Liabilities	18,766	23,356
Commitments and contingencies (Note 22)
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 4,212 in 2014 and 4,369 in 2013, liquidation value of $50 per share	0	0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2014 and 2013	221	221
Capital in excess of par value of stock	1,507	1,922
Accumulated other comprehensive loss	(2,425)	(2,141)
Retained earnings	32,541	32,952
Less cost of treasury stock - 547 million common shares in 2014 and 559 million in 2013	(16,992)	(17,800)
Total Bristol-Myers Squibb Company Shareholders' Equity	14,852	15,154
Noncontrolling interest	131	82
Total Equity	14,983	15,236
Total Liabilities and Equity	$ 33,749	$ 38,592